Tenax Therapeutics Inc (TENX)
3.70
+0.02
(+0.54%)
USD |
NASDAQ |
Apr 19, 16:00
3.70
0.00 (0.00%)
After-Hours: 20:00
Tenax Therapeutics Cash from Financing (TTM): 13.57M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 13.57M |
September 30, 2023 | 13.75M |
June 30, 2023 | 13.83M |
March 31, 2023 | 21.72M |
December 31, 2022 | 7.931M |
September 30, 2022 | 7.929M |
June 30, 2022 | 17.21M |
March 31, 2022 | 9.421M |
December 31, 2021 | 9.737M |
September 30, 2021 | 9.736M |
June 30, 2021 | 7.076M |
March 31, 2021 | 9.012M |
December 31, 2020 | 10.60M |
September 30, 2020 | 10.60M |
June 30, 2020 | 4.065M |
March 31, 2020 | 2.13M |
December 31, 2019 | 0.0965M |
September 30, 2019 | 9.004M |
June 30, 2019 | 9.004M |
March 31, 2019 | 9.004M |
December 31, 2018 | 8.907M |
September 30, 2018 | |
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 |
Date | Value |
---|---|
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
October 31, 2015 | |
September 30, 2015 | |
July 31, 2015 | 0.0014M |
April 30, 2015 | 0.0372M |
March 31, 2015 | 0.2847M |
January 31, 2015 | 55.33M |
October 31, 2014 | 61.72M |
July 31, 2014 | 62.26M |
April 30, 2014 | 66.95M |
January 31, 2014 | 13.39M |
October 31, 2013 | 6.933M |
July 31, 2013 | 6.400M |
April 30, 2013 | 3.973M |
January 31, 2013 | 2.609M |
October 31, 2012 | 6.114M |
July 31, 2012 | 6.739M |
April 30, 2012 | 9.467M |
January 31, 2012 | 11.67M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.0965M
Minimum
Dec 2019
21.72M
Maximum
Mar 2023
9.811M
Average
9.421M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
BioRestorative Therapies Inc | 2.351M |
Immunome Inc | 116.41M |
Jasper Therapeutics Inc | 100.97M |
Cadrenal Therapeutics Inc | 11.90M |
GE HealthCare Technologies Inc | -478.00M |